temozolomide has been researched along with sirolimus in 40 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 8 (20.00) | 29.6817 |
2010's | 29 (72.50) | 24.3611 |
2020's | 3 (7.50) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Liu, Y; Xu, Z; Zhao, SJ | 1 |
Marx, J | 1 |
Alemany, R; Alonso, MM; Bekele, NB; Fueyo, J; Gomez-Manzano, C; Jiang, H; Piao, Y; Yung, WK | 1 |
Banerjee, D; Garbow, JR; Gutmann, DH; Hegedus, B; Perry, A; Rothermich, S; Rubin, JB; Yeh, TH | 1 |
Lefranc, F | 1 |
Liau, LM; Salgaller, ML | 1 |
Aoki, H; Fujiwara, T; Georgescu, MM; Hashimoto, Y; Hayashi, Y; Hess, KR; Iwado, E; Kawamura, H; Kondo, S; Kondo, Y; Mills, GB; Sawaya, R; Urata, Y; Yokoyama, T | 1 |
Belohlavek, C; Christmann, M; Jöst, E; Kaina, B; Lennerz, V; Naumann, SC; Roos, WP; Schmidt, CW | 1 |
Eriksson, B | 1 |
Brown, PD; Buckner, JC; Galanis, E; Giannini, C; Jaeckle, KA; McGraw, S; Peller, PJ; Sarkaria, JN; Uhm, JH; Wu, W | 1 |
Borson-Chazot, F; Ducray, F; Favrel, V; Honnorat, J; Jouanneau, E; Raverot, G; Trouillas, J; Wierinckx, A | 1 |
Easaw, J; Eisenhauer, E; Kavan, P; Lwin, Z; Macdonald, D; Macneil, M; Mason, WP; McIntosh, L; Thiessen, B; Urva, S | 1 |
Calderaro, F; Cevenini, G; Comincini, S; Miracco, C; Palumbo, S; Pirtoli, L; Tini, P; Toscano, M | 1 |
Reidy-Lagunes, D; Thornton, R | 1 |
Brinker, BT; Hainsworth, JD; Shepard, GC; Shih, KC; Spigel, DR; Tillinghast, GW | 1 |
Igarashi, H; Ito, T; Jensen, RT; Takayanagi, R | 1 |
Allred, JB; Creagan, ET; Dronca, RS; Kaur, JS; Lieser, EA; Maples, WJ; Marchello, BT; Markovic, SN; Moore, TD; Nevala, WK; Perez, DG; Pockaj, BA; Thompson, M | 1 |
Bischoff, P; Burckel, H; Josset, E; Noël, G | 1 |
Chinnaiyan, P; Corn, BW; Dipetrillo, TA; Mehta, MP; Rojiani, AM; Wen, PY; Wendland, M; Won, M | 1 |
Allen, J; Blaszkowsky, L; Chan, JA; Gonzalez, M; Kulke, MH; Meyerhardt, J; Regan, E; Ryan, DP; Stuart, K; Wadlow, R; Zheng, H; Zhu, AX | 1 |
Adamson, PC; Ahern, C; Bagatell, R; Blaney, S; Fox, E; Ingle, AM; Little, AR; Norris, R; Voss, S; Weigel, BJ | 1 |
Allavena, G; Angeletti, F; Comincini, S; Manai, F; Miracco, C; Palumbo, S; Pirtoli, L; Tini, P; Toscano, M | 1 |
Ferolla, P | 1 |
Corbacioglu, S; Debatin, KM; Engelke, J; Fulda, S; Halatsch, ME; Karpel-Massler, G; Nonnenmacher, L; Simmet, T; Westhoff, MA | 1 |
Bischoff, P; Burckel, H; Denis, JM; Gueulette, J; Josset, E; Noël, G; Slabbert, J | 1 |
Bueno e Silva, MM; Filippi-Chiela, EC; Lenz, G; Thomé, MP | 1 |
Chong, DQ; Dinesh, N; Ho, IA; Ho, MM; Lai, SH; Lam, PY; Newman, JP; Ng, WH; Sia, KC; Tham, CK; Toh, XY; Yulyana, Y | 1 |
Dmitrenko, VV; Stepanenko, AA | 1 |
Chakrabarti, M; Ray, SK | 1 |
Dai, S; Gong, Z; Qian, L; Sun, L; Xu, Z; Yan, Y | 1 |
Aldaz, P; Arrizabalaga, O; Barrena, C; Carrasco-Garcia, E; Garcia, I; Garros-Regulez, L; Lovell-Badge, R; Manterola, L; Matheu, A; Moncho-Amor, V; Moreno-Cugnon, L; Pollard, S; Ruiz, I; Sampron, N; Villanua, J | 1 |
Bady, P; Brandes, AA; Campone, M; Frenel, JS; Golfinopoulos, V; Gorlia, T; Hamou, MF; Hegi, ME; Homicsko, K; Hopkins, K; Kosch, M; Lhermitte, B; Marosi, C; Pesce, G; Platten, M; Ricard, D; Roth, P; Steuve, J; Stupp, R; Taphoorn, MJ; van den Bent, MJ; Villa, S; Weller, M; Weyerbrock, A; Wick, A; Wick, W | 1 |
Beck, D; Bonin, M; Garbe, C; Kosnopfel, C; Krieg, K; Lasithiotakis, K; Meier, F; Niessner, H; Sinnberg, T; Wanke, I | 1 |
Alvarez, AA; Cheng, SY; Hu, B; Huang, T; James, CD; Nakano, I; Sastry, N; Song, X; Sulman, EP; Wan, X; Yang, Y | 1 |
Chen, G; Li, PA; Qi, Q; Wilkison, S; Zimmerman, MA | 1 |
Corbacioglu, S; Heise, T; Leister, J; Matthes, M; Penkivech, G; Sommer, G; Waetzig, R | 1 |
Chen, TC; Cho, HY; Fu, J; Hofman, FM; Minea, RO; Ou, M; Schönthal, AH; Stathopoulos, A; Swenson, SD; Tang, L; Thein, TZ; Wang, W | 1 |
8 review(s) available for temozolomide and sirolimus
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles | 2019 |
Current status of clinical trials for glioblastoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Biocompatible Materials; Brain Neoplasms; Cancer Vaccines; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Decanoic Acids; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Gefitinib; Glioblastoma; Humans; Imatinib Mesylate; Immunotoxins; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Piperazines; Polyesters; Protein Kinase Inhibitors; Proteins; Pyrimidines; Quinazolines; Sirolimus; Temozolomide; TOR Serine-Threonine Kinases; Transcription Factors | 2006 |
New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?
Topics: Antineoplastic Agents; Capecitabine; Dacarbazine; Deoxycytidine; Drug Therapy; Everolimus; Fluorouracil; Humans; Indoles; Neuroendocrine Tumors; Octreotide; Pyrroles; Sirolimus; Sunitinib; Temozolomide; Treatment Outcome | 2010 |
Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoid Tumor; Combined Modality Therapy; Dacarbazine; Embolization, Therapeutic; Everolimus; Humans; Immunosuppressive Agents; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Streptozocin; Sunitinib; Temozolomide; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factors; Yttrium Radioisotopes | 2012 |
[Current status and therapeutic strategy for pancreatic neuroendocrine tumors in Japan].
Topics: Antineoplastic Agents; Dacarbazine; Digestive System Surgical Procedures; Everolimus; Humans; Immunosuppressive Agents; Indoles; Japan; Molecular Targeted Therapy; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Somatostatin; Streptozocin; Sunitinib; Temozolomide | 2012 |
Medical treatment of advanced thoracic neuroendocrine tumors.
Topics: Adrenocorticotropic Hormone; Antineoplastic Agents; Dacarbazine; Everolimus; Humans; Neuroendocrine Tumors; Sirolimus; Temozolomide; Thoracic Neoplasms | 2014 |
Targeting autophagy to sensitive glioma to temozolomide treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chloroquine; Clinical Trials as Topic; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; Glioblastoma; Humans; Sirolimus; Temozolomide | 2016 |
8 trial(s) available for temozolomide and sirolimus
Article | Year |
---|---|
North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Everolimus; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Sirolimus; Temozolomide | 2011 |
A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Combinations; Everolimus; Female; Glioblastoma; Humans; Immunosuppressive Agents; Male; Middle Aged; PTEN Phosphohydrolase; Sirolimus; Temozolomide; Young Adult | 2012 |
Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Everolimus; Female; Glioblastoma; Humans; Immunosuppressive Agents; Male; Middle Aged; Sirolimus; Temozolomide; Young Adult | 2012 |
Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Everolimus; Female; Humans; Induction Chemotherapy; Male; Melanoma; Middle Aged; Sirolimus; Skin Neoplasms; Temozolomide; TOR Serine-Threonine Kinases; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Dose Fractionation, Radiation; Everolimus; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Sirolimus; Temozolomide | 2013 |
A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Everolimus; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Prospective Studies; Sirolimus; Temozolomide; Treatment Outcome | 2013 |
Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Follow-Up Studies; Humans; Infant; Irinotecan; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasms; Prognosis; Remission Induction; Sirolimus; Temozolomide; Young Adult | 2014 |
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082).
Topics: Adult; Aged; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Promoter Regions, Genetic; Proportional Hazards Models; Sirolimus; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2016 |
24 other study(ies) available for temozolomide and sirolimus
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Bibliography. Current world literature. Therapeutic modalities.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Dacarbazine; Genetic Therapy; Heat-Shock Proteins; Humans; Immunotherapy; Interferons; Oxides; Radiotherapy; Sirolimus; Temozolomide; Vitamin D | 2003 |
Autophagy: is it cancer's friend or foe?
Topics: Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cell Survival; Chloroquine; Dacarbazine; Genes, Tumor Suppressor; Humans; Membrane Proteins; Mice; Neoplasms; Oncogenes; Proteins; Sirolimus; Temozolomide | 2006 |
Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Everolimus; Glioma; Humans; Mice; Mice, Nude; Neoplasms, Experimental; Oncolytic Virotherapy; Sirolimus; Temozolomide | 2007 |
Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Proliferation; Dacarbazine; Disease Models, Animal; Eye Neoplasms; Magnetic Resonance Imaging; Mice; Mice, Transgenic; Neurofibromin 1; Optic Nerve Glioma; Protein Kinases; Signal Transduction; Sirolimus; Temozolomide; TOR Serine-Threonine Kinases | 2008 |
[Glioblastomas are resistant to apoptosis but less resistant to the autophagic process].
Topics: Algorithms; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Movement; Clinical Trials as Topic; Dacarbazine; Forecasting; Glioblastoma; Humans; Prognosis; Sirolimus; Temozolomide; Transcription Factors | 2007 |
Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells.
Topics: Adenoviridae; Animals; Autophagy; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Genetic Therapy; Glioblastoma; Mice; Oncolytic Virotherapy; Oncolytic Viruses; Sirolimus; Temozolomide | 2008 |
Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Collagen Type XI; Dacarbazine; DNA Breaks, Double-Stranded; DNA Mismatch Repair; DNA Modification Methylases; DNA Repair Enzymes; Enzyme Activation; Everolimus; Humans; Melanoma; Necrosis; Phosphorylation; Sirolimus; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2009 |
New targeted therapies in pituitary carcinoma resistant to temozolomide.
Topics: Dacarbazine; Drug Resistance, Neoplasm; Everolimus; Humans; Male; Middle Aged; Pituitary Neoplasms; Sirolimus; Temozolomide | 2012 |
Different involvement of autophagy in human malignant glioma cell lines undergoing irradiation and temozolomide combined treatments.
Topics: Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 5; Beclin-1; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Membrane Proteins; Microtubule-Associated Proteins; Radiation-Sensitizing Agents; RNA Interference; RNA, Small Interfering; Sirolimus; Temozolomide | 2012 |
The mTOR inhibitor RAD001 potentiates autophagic cell death induced by temozolomide in a glioblastoma cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Blotting, Western; Brain Neoplasms; Cell Proliferation; Cesium Radioisotopes; Dacarbazine; Drug Synergism; Everolimus; Flow Cytometry; Gamma Rays; Glioblastoma; Humans; Sirolimus; Temozolomide; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2013 |
Combined EGFR and autophagy modulation impairs cell migration and enhances radiosensitivity in human glioblastoma cells.
Topics: Autophagy; Autophagy-Related Protein 7; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Clone Cells; Dacarbazine; Drug Resistance, Neoplasm; ErbB Receptors; Gene Silencing; Glioblastoma; Humans; Radiation Tolerance; Radiation, Ionizing; RNA, Small Interfering; Sirolimus; Temozolomide; Transfection; Ubiquitin-Activating Enzymes | 2014 |
RIST: a potent new combination therapy for glioblastoma.
Topics: Adolescent; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Child; Dacarbazine; Female; Glioblastoma; Humans; Indoles; Irinotecan; Male; Membrane Potential, Mitochondrial; Mice, Inbred NOD; Molecular Targeted Therapy; Pyrroles; Sirolimus; Sunitinib; Temozolomide; Xenograft Model Antitumor Assays | 2015 |
Combination of the mTOR inhibitor RAD001 with temozolomide and radiation effectively inhibits the growth of glioblastoma cells in culture.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Proliferation; Cell Survival; Dacarbazine; DNA Damage; Dose-Response Relationship, Radiation; Everolimus; Gamma Rays; Glioblastoma; Histones; Humans; Linear Energy Transfer; Sirolimus; Temozolomide; TOR Serine-Threonine Kinases | 2015 |
Single-cell analysis challenges the connection between autophagy and senescence induced by DNA damage.
Topics: AMP-Activated Protein Kinases; Apoptosis; Autophagy; Autophagy-Related Protein-1 Homolog; Cell Cycle Checkpoints; Cell Line, Tumor; Cellular Senescence; Dacarbazine; DNA Damage; Enzyme Activation; Glioma; Green Fluorescent Proteins; Humans; Intracellular Signaling Peptides and Proteins; Models, Biological; p38 Mitogen-Activated Protein Kinases; Phenotype; Protein Serine-Threonine Kinases; Single-Cell Analysis; Sirolimus; Temozolomide; Time Factors; TOR Serine-Threonine Kinases | 2015 |
Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; ErbB Receptors; Glioblastoma; Humans; Mutation; Sirolimus; Temozolomide | 2015 |
Pitfalls of the MTT assay: Direct and off-target effects of inhibitors can result in over/underestimation of cell viability.
Topics: Animals; Biological Assay; Cell Count; Cell Line, Tumor; Cell Survival; Dacarbazine; Female; Formazans; Humans; Inhibitory Concentration 50; Rats; Rats, Wistar; Sirolimus; Temozolomide; Tetrazolium Salts | 2015 |
Anti-tumor activities of luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Carmustine; Caspase 8; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Female; Glioblastoma; Humans; Luteolin; Mice; Mice, Nude; MicroRNAs; Signal Transduction; Silybin; Silymarin; Sirolimus; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; Humans; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Sirolimus; SOX9 Transcription Factor; SOXB1 Transcription Factors; Temozolomide; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2016 |
Combined activity of temozolomide and the mTOR inhibitor temsirolimus in metastatic melanoma involves DKK1.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Early Growth Response Protein 1; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Transfer Techniques; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Lentivirus; Melanoma; Membrane Proteins; Oligonucleotide Array Sequence Analysis; Signal Transduction; Sirolimus; Skin; Skin Neoplasms; Sulfonamides; Temozolomide; TOR Serine-Threonine Kinases; Vemurafenib | 2017 |
MIR93 (microRNA -93) regulates tumorigenicity and therapy response of glioblastoma by targeting autophagy.
Topics: Animals; Autophagy; Autophagy-Related Proteins; Glioma; HEK293 Cells; Humans; Mice, Nude; MicroRNAs; Neoplastic Stem Cells; Sirolimus; Temozolomide; Transplantation, Heterologous | 2019 |
Mitochondrial dysfunction contributes to Rapamycin-induced apoptosis of Human Glioblastoma Cells - A synergistic effect with Temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Drug Synergism; Glioblastoma; Humans; Membrane Potential, Mitochondrial; Mitochondria; Mitochondrial Dynamics; Reactive Oxygen Species; Signal Transduction; Sirolimus; Temozolomide; TOR Serine-Threonine Kinases | 2020 |
Comparing mTOR inhibitor Rapamycin with Torin-2 within the RIST molecular-targeted regimen in neuroblastoma cells.
Topics: Administration, Metronomic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Indoles; Inhibitory Concentration 50; Irinotecan; Naphthyridines; Neuroblastoma; Purines; Pyrimidines; Signal Transduction; Sirolimus; Temozolomide; Thiourea; TOR Serine-Threonine Kinases | 2021 |
Inhibition of autophagy and induction of glioblastoma cell death by NEO214, a perillyl alcohol-rolipram conjugate.
Topics: Autophagy; Cell Death; Chloroquine; Glioblastoma; Glioma; Humans; Lysosomes; Monoterpenes; Rolipram; Sirolimus; Temozolomide; TOR Serine-Threonine Kinases | 2023 |